TCIM
TGTX icon

TIAA CREF Investment Management’s TG Therapeutics TGTX Stock Holding History

TIAA CREF Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.02M Buy
127,307
+14,848
+13% +$80.2K ﹤0.01% 2310
2018
Q4 		$461K Hold
112,459
– – ﹤0.01% 2601
2018
Q3 		$630K Sell
112,459
-11,965
-10% -$137K ﹤0.01% 2623
2018
Q2 		$1.64M Buy
124,424
+1,958
+2% +$26.9K ﹤0.01% 2281
2018
Q1 		$1.74M Sell
122,466
-544
-0.4% -$6.95K ﹤0.01% 2175
2017
Q4 		$1.01M Buy
123,010
+372
+0.3% +$3.25K ﹤0.01% 2453
2017
Q3 		$1.45M Sell
122,638
-43,103
-26% -$491K ﹤0.01% 2331
2017
Q2 		$1.67M Buy
165,741
+65,426
+65% +$732K ﹤0.01% 2294
2017
Q1 		$1.17M Sell
100,315
-3,948
-4% -$28.3K ﹤0.01% 2432
2016
Q4 		$485K Sell
104,263
-10,835
-9% -$63.5K ﹤0.01% 2864
2016
Q3 		$891 Sell
115,098
-630
-0.5% -$4.05K ﹤0.01% 2598
2016
Q2 		$701K Buy
115,728
+2,788
+2% +$22.7K ﹤0.01% 2701
2016
Q1 		$962K Hold
112,940
– – ﹤0.01% 2496
2015
Q4 		$1.35M Sell
112,940
-4,855
-4% -$61.3K ﹤0.01% 2397
2015
Q3 		$1.19M Hold
117,795
– – ﹤0.01% 2465
2015
Q2 		$1.95M Buy
117,795
+30,855
+35% +$489K ﹤0.01% 2315
2015
Q1 		$1.35M Buy
86,940
+6,330
+8% +$95.8K ﹤0.01% 2468
2014
Q4 		$1.28M Buy
80,610
+1,131
+1% +$14.7K ﹤0.01% 2513
2014
Q3 		$848K Sell
79,479
-18,236
-19% -$169K ﹤0.01% 2734
2014
Q2 		$918K Buy
97,715
+21,475
+28% +$137K ﹤0.01% 2763
2014
Q1 		$526K Buy
76,240
+15,400
+25% +$91.1K ﹤0.01% 2922
2013
Q4 		$237K Sell
60,840
-4,091
-6% -$16.5K ﹤0.01% 3074
2013
Q3 		$330K Sell
64,931
-12,959
-17% -$79.2K ﹤0.01% 3018
2013
Q2 		$498K Buy
+77,890
New +$499K ﹤0.01% 2934

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TIAA CREF Investment Management's TGTX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its TG Therapeutics (TGTX) stake by 13% in Q1 2019, buying an estimated $80.2K and bringing the position to 127,307 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

TIAA CREF Investment Management first reported a position in TGTX in Q2 2013 and has held it in 24 quarters since. The position peaked at $1.95M in Q2 2015. 113 funds tracked by Wall St. Rank hold TGTX as of Q1 2019.

  • TIAA CREF Investment Management held 127,307 shares of TG Therapeutics worth $1.02M as of Q1 2019.
  • TIAA CREF Investment Management bought 14,848 TG Therapeutics shares in Q1 2019, an estimated $80.2K.
  • TG Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2310 holding.
  • TIAA CREF Investment Management first reported a position in TG Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's TG Therapeutics position peaked at $1.95M in Q2 2015.
  • 113 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.